Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)

Margaretha G.m Roemer ,Margaret A Shipp,Anas Younes,Azra H Ligon,John Kuruvilla,Voravit Ratanatharathorn,John M Timmerman,Benedetto Farsaci,Kazunobu Kato,Philippe Armand,Andreas Engert,Pier Luigi Zinzani,Anne Sumbul,Jonathon B Cohen,Graham P Collins,Armando Santoro,Marek Trněný ,Stephen M Ansell ,Kerry J Savage ,Robert A Redd ,Scott J Rodig ,Donna Neuberg ,Michelle A Fanale

doi:10.1182/blood.v128.22.2923.2923

Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)

Margaretha G.m Roemer , Margaret A Shipp + Show 21 more

Open Access

https://doi.org/10.1182/blood.v128.22.2923.2923

Copy DOI

Journal: Blood	Publication Date: Dec 2, 2016
Citations: 6

Affiliation: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, Princess Margaret Cancer Centre, Karmanos Cancer Institute, UCLA Medical Center, Bristol-Myers Squibb (United States), Harvard University, University Hospital Cologne, University of Bologna, Emory University, Churchill Hospital, Humanitas University, Charles University, Mayo Clinic, BC Cancer Agency, Dana-Farber/Harvard Cancer Center, The University of Texas MD Anderson Cancer Center

#Hodgkin Reed-Sternberg Cells #Advisory Committees + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.